RT Journal Article
SR Electronic
T1 Trajectories of gene expression, seasonal influenza, and within-host seasonal immunity: transfer value to covid-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.01.22271679
DO 10.1101/2022.03.01.22271679
A1 Eiliv Lund
A1 Marit Holden
A1 Lill-Tove Rasmussen Busund
A1 Igor Snapkov
A1 Nikita Shvetsov
A1 Lars Holden
YR 2022
UL http://medrxiv.org/content/early/2022/03/11/2022.03.01.22271679.abstract
AB As a novel approach we will combine trajectories or longitudinal studies of gene expression with information on annual influenza epidemics. Seasonality of gene expression in immune cells from blood could be a consequence of within-host seasonal immunity interacting with the seasonal pandemics of influenza (flu) in temperate regions and, thus, with potential valuable analogy transfer to the proposed seasonal development of covid-19.Here we operationalized within-host immunity as genes with both a significant seasonal term and a significant flu term in the sine-cosine model. Information on gene expression was based on microarray using RNase buffered blood samples collected randomly from a population-based cohort of Norwegian middle-aged women in 2003-2006, The Norwegian Women and Cancer (NOWAC) study. The unique discovery (N=425) and replication (N=432) design were based on identical sampling and preprocessing. Data on proportion of sick leaves due to flu, and the flu intensities per week was obtained from the National Institute of Public Health, giving a semi-ecological analysis.The discovery analysis found 2942 (48.1%) significant genes in a generalized seasonal model over four years. For 1051 within-host genes both the seasonal and the flu term were significant. These genes followed closely the flu intensities. The trajectories showed slightly more genes with a maximum in early winter than in late summer. Moving the flu intensity forward in time indicated a better fit 3-4 weeks before the observed influenza. In the replication analyses, 369 genes (35.1% of 1051) were significant. Exclusion of genes with unknown functions and with more than a season in difference reduced the number of genes in the discovery dataset to 305, illustrating the variability in the measurements and the problem in assessing weak biological relationships. Thus, we found for the first time a clear seasonality in gene expression with marked responses to the annual seasonal influenza in a unique discovery – replication design. Hypothetically, this could support the within-host seasonal immunity concept.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by a grant given to Eiliv Lund from the European Research Council (ERC-AdG 232997 TICE), and a donation from Halfdan Jacobsen og frues legat (The Norwegian Cancer Society). The funders had no part in the study design, analyses or publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The NOWAC study was approved by the Norwegian Data Inspectorate and recommended by the Regional Ethical Committee of Northern Norway (REC North). The linkages of the NOWAC database to national registries such as the Cancer Registry of Norway and registries on death and emigration have also been approved. The women were informed about these linkages in the letter of invitation. Furthermore, the collection and storing of human biological material was approved by the REC North in accordance with the Norwegian Biobank Act. The linkages between Cancer Registry data and NOWAC study participants were performed at Statistics Norway, and the dataset was fully anonymized before it was made available to the authors. Information on breast cancer was used in this study to sample the random, matched controls. The Norwegian Data Protection Authority gave NOWAC exemption from the duty of confidentiality and permission to handle personal data (Datatilsynet, ref. 07/00030-2/cbr).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.